[Bladder cancer and new drugs].
Cisplatin-based chemotherapy (MVAC : cisplatin, methotrexate, adriamycin, vinblastine ; or GC : cisplatin, gemcitabine) has been the standard of care for patients with advanced urothelial tumor during the last twenty years. Greater knowledge in the molecular biology of bladder cancer lead to the identification of promising target such as EGFR, HER2, or VEGF-VEGFR pathways. The role of targeted therapies as monotherapy, in combination with chemotheray or as maintenance post-chemotherapy is currently under study.
Institut Gustave-Roussy, Département de médecine, université Paris-XI, Hautes-Bruyères, 94805 Villejuif, France. christophe.massard@igr.fr <christophe.massard@igr.fr>
C
C
Massard
B
B
Albouy
M
M
Gross-Goupil
A
A
Ravaud
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor